# Tanabe Pharma America, Inc. clinical trials: 20 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials with Tanabe Pharma America, Inc. as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Tanabe Pharma America, Inc.: 20 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/tanabe-pharma-america-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 24, 2025 | NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | Tanabe Pharma America, Inc. | Phase 1/2 | Recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06943521) |
| November 22, 2023 | NCT06144840 | INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP | Tanabe Pharma America, Inc. | Phase 3 | Completed | Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP) | 165 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06144840) |
| February 15, 2022 | NCT05241535 | Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects | Tanabe Pharma America, Inc. | Phase 1 | Completed | Healthy Subjects | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05241535) |
| August 16, 2021 | NCT05005975 | Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or... | Tanabe Pharma America, Inc. | Phase 3 | Active not recruiting | EPP, XLP | 286 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05005975) |
| March 11, 2021 | NCT04793295 | Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects | Tanabe Pharma America, Inc. | Phase 1 | Completed | Healthy Subjects | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04793295) |
| December 24, 2020 | NCT04683848 | Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury | Tanabe Pharma America, Inc. | Phase 2 | Completed | Spinal Cord Injury | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04683848) |
| December 7, 2020 | NCT04656795 | PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function | Tanabe Pharma America, Inc. | Phase 1 | Completed | Renal Impairment, Normal Renal Function | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04656795) |
| June 19, 2020 | NCT04440592 | Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis | Tanabe Pharma America, Inc. | Phase 2 | Completed | Diffuse Cutaneous Systemic Sclerosis | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04440592) |
| May 26, 2020 | NCT04402489 | Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria | Tanabe Pharma America, Inc. | Phase 3 | Completed | EPP, XLP | 184 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04402489) |
| October 4, 2019 | NCT04116476 | Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function | Tanabe Pharma America, Inc. | Phase 1 | Completed | Mild and Moderate Hepatic Impairment | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04116476) |
| September 20, 2019 | NCT04096950 | Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury | Tanabe Pharma America, Inc. | Phase 1 | Completed | Spinal Cord Injury | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04096950) |
| February 15, 2019 | NCT03840993 | Safety and Efficacy Study of MT-2990 in Women With Endometriosis | Tanabe Pharma America, Inc. | Phase 2 | Completed | Endometrial Related Pain | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03840993) |
| January 18, 2019 | NCT03809039 | A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-6345 in Healthy Subjects | Tanabe Pharma America, Inc. | Phase 1 | Terminated | Healthy | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03809039) |
| September 27, 2018 | NCT03688022 | Relative Bioavailability and Drug-drug Interaction Study With MT-7117 and a Proton Pump Inhibitor | Tanabe Pharma America, Inc. | Phase 1 | Completed | Healthy Volunteer | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03688022) |
| May 30, 2018 | NCT03541200 | Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms | Tanabe Pharma America, Inc. | Phase 2 | Completed | Vasomotor Symptoms (VMS) | 190 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03541200) |
| May 9, 2018 | NCT03520036 | Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria | Tanabe Pharma America, Inc. | Phase 2 | Completed | Erythropoietic Protoporphyria (EPP) | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03520036) |
| April 19, 2018 | NCT03503266 | Mass Balance Study With MT-7117 | Tanabe Pharma America, Inc. | Phase 1 | Completed | Healthy Volunteer | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03503266) |
| March 20, 2018 | NCT03471130 | Definitive QT Study With MT-8554 | Tanabe Pharma America, Inc. | Phase 1 | Completed | Healthy Volunteer | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03471130) |
| December 22, 2017 | NCT03381404 | Mass Balance Study With MT-8554 | Tanabe Pharma America, Inc. | Phase 1 | Completed | Healthy Volunteer | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03381404) |
| September 25, 2017 | NCT03291067 | MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women | Tanabe Pharma America, Inc. | Phase 2 | Completed | Menopause Hot Flashes | 375 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03291067) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 10 |
| Phase 1/2 | 1 |
| Phase 2 | 6 |
| Phase 3 | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 17 |
| Terminated | 1 |
| Active not recruiting | 1 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Protoporphyria, Erythropoietic | 2 |
| Lymphoma, Follicular | 2 |
| Spinal Cord Injuries | 2 |
| Scleroderma, Diffuse | 1 |
| Renal Insufficiency | 1 |
| Protoporphyria, Erythropoietic, X-Linked Dominant | 1 |
| Endometriosis | 1 |
| Squamous Cell Carcinoma of Head and Neck | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Esophageal Neoplasms | 1 |
| Stomach Neoplasms | 1 |
| Biliary Tract Neoplasms | 1 |
| Breast Neoplasms | 1 |
| Ovarian Neoplasms | 1 |
| Uterine Cervical Neoplasms | 1 |
| Endometrial Neoplasms | 1 |
| Prostatic Neoplasms | 1 |
| Carcinoma, Transitional Cell | 1 |
| Neuroendocrine Tumors | 1 |
| Carcinoma, Neuroendocrine | 1 |
| Sarcoma | 1 |
| Carcinoma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Criminal defense law firms in the United States](https://specstream.ai/data/businesses/criminal-defense-law-firms/united-states)
- [Motels in the United States](https://specstream.ai/data/businesses/motels/united-states)
- [Wineries in the United States](https://specstream.ai/data/businesses/wineries/united-states)
- [Family practice clinics in the United States](https://specstream.ai/data/businesses/family-practice-clinics/united-states)
- [Pool and hot tub services in the United States](https://specstream.ai/data/businesses/pool-and-hot-tub-services/united-states)
- [B2B radio and television commercials companies in the United States](https://specstream.ai/data/businesses/b2b-radio-and-television-commercials-companies/united-states)
